US Senate Resolution Declaring Lung Cancer a National Public Health Priority Unanimously Adopted

Publication
Article
OncologyONCOLOGY Vol 20 No 7
Volume 20
Issue 7

The Lung Cancer Alliance hailed the US Senate's action declaring lung cancer a national public health priority and calling for an interagency coordinated attack on the number one cancer killer. Laurie Fenton, president of the Lung Cancer Alliance, praised Senator Chuck Hagel (R-NE) and Senator Hillary Clinton (D-NY) for their leadership in reaching across party lines to give the resolution their full support and expedite its passage by the Senate.

 

The Lung Cancer Alliance hailed the US Senate's action declaring lung cancer a national public health priority and calling for an interagency coordinated attack on the number one cancer killer. Laurie Fenton, president of the Lung Cancer Alliance, praised Senator Chuck Hagel (R-NE) and Senator Hillary Clinton (D-NY) for their leadership in reaching across party lines to give the resolution their full support and expedite its passage by the Senate.

Five weeks ago, Hagel and Clinton jointly introduced the resolution, SRes 408, which calls lung cancer a public health priority and includes a blueprint for several federal agencies-including the Departments of Defense, Veterans Affairs, Health and Human Services, and the Food and Drug Administration-to work together in reducing lung cancer's high mortality numbers.

"A resolution, even one passed unanimously, does not legally force the agencies to act," Fenton noted. "However, the political message coming from the Senate is loud and clear, and the rarely seen speed with which it was passed-just 5 weeks after introduction-boosts the volume even louder."

The resolution calls on the President to declare lung cancer a public health priority and to increase funding for research, screening, and graduate medical education programs in thoracic care and surgery. Expedited approval procedures for lung cancer drugs, new screening and treatment programs for veterans and military personnel, and a pilot screening program under Medicare are also included in this declaration.

A similar resolution introduced by Congressman Clay Shaw (R-FL), HRes 739, is currently pending in the House of Representatives.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content